PDF herunterladen
Semin intervent Radiol 2022; 39(04): 394-399
DOI: 10.1055/s-0042-1757318
Review Article

A Brief Review of Thrombolytics for Venous Interventions

Sukhdeep K. Grewal   *
1   Department of Radiology and Medical Imaging, Vascular and Interventional Radiology, University of Virginia Health, Charlottesville, Virginia
,
Amanda L. Hedrick   *
2   Department of Medicine, Critical Care Pharmacology, University of Virginia Health, Charlottesville, Virginia
,
Louise Man
3   Department of Medicine, Hematology and Oncology, University of Virginia Health, Charlottesville, Virginia
,
Aditya M. Sharma
4   Department of Medicine, Cardiovascular Medicine, University of Virginia Health, Charlottesville, Virginia
,
Kush R. Desai
5   Interventional Radiology, Department of Radiology, Northwestern University, Chicago, Illinois
,
Minhaj S. Khaja
1   Department of Radiology and Medical Imaging, Vascular and Interventional Radiology, University of Virginia Health, Charlottesville, Virginia
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Anticoagulation continues to be the mainstay of therapy for the management of venous thromboembolism. However, anticoagulation does not lead to the breakdown or dissolving of the thrombus. In an acute pulmonary embolism, extensive thrombus burden can be associated with a high risk for early decompensation, and in acute deep venous thrombosis, it can be associated with an increased risk for phlegmasia. In addition, residual thrombosis can be associated with chronic thromboembolic pulmonary hypertension and postthrombotic syndrome in a chronic setting. Thrombolytic therapy is a crucial therapeutic choice in treating venous thromboembolism for thrombus resolution. Historically, it was administered systemically and was associated with high bleeding rates, particularly major bleeding, including intracranial bleeding. In the last two decades, there has been a significant increase in catheter-based therapies with and without ultrasound, where lower doses of thrombolytic agents are utilized, potentially reducing the risk for major bleeding events and improving the odds of reducing the thrombus burden. In this article, we provide an overview of several thrombolytic therapies, including delivery methods, doses, and outcomes.

Keywords

thrombolysis - alteplase - venous thromboembolic disease - venous thromboembolism - interventional radiology

* S.K.G. and A.L.H. are co–first authors.




Publikationsverlauf

Artikel online veröffentlicht:
17. November 2022

© 2022. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

 

  • References

  • 1 Ortel TL, Neumann I, Ageno W. et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv 2020; 4 (19) 4693-4738
    CrossrefPubMedGoogle Scholar
  • 2 Huang W, Goldberg RJ, Anderson FA, Kiefe CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE study (1985-2009). Am J Med 2014; 127 (09) 829-39 .e5
    CrossrefPubMedGoogle Scholar
  • 3 Kahn SR, Shrier I, Julian JA. et al. Determinants and time course of the postthrombotic syndrome after acute deep venous thrombosis. Ann Intern Med 2008; 149 (10) 698-707
    CrossrefPubMedGoogle Scholar
  • 4 Vedantham S, Goldhaber SZ, Julian JA. et al; ATTRACT Trial Investigators. Pharmacomechanical catheter-directed thrombolysis for deep-vein thrombosis. N Engl J Med 2017; 377 (23) 2240-2252
    CrossrefPubMedGoogle Scholar
  • 5 Martin C, Sobolewski K, Bridgeman P, Boutsikaris D. Systemic thrombolysis for pulmonary embolism: a review. P&T 2016; 41 (12) 770-775
    PubMedGoogle Scholar
  • 6 Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J Stroke 2013; 15 (02) 90-98
    CrossrefPubMedGoogle Scholar
  • 7 Dotter CT, Rösch J, Seaman AJ. Selective clot lysis with low-dose streptokinase. Radiology 1974; 111 (01) 31-37
    CrossrefPubMedGoogle Scholar
  • 8 Brayfield A. Martindale: The Complete Drug Reference. 40th ed. Pharmaceutical Press; 2020
    Google Scholar
  • 9 Ucar EY. Update on thrombolytic therapy in acute pulmonary thromboembolism. Eurasian J Med 2019; 51 (02) 186-190
    PubMedGoogle Scholar
  • 10 Sikri N, Bardia A. A history of streptokinase use in acute myocardial infarction. Tex Heart Inst J 2007; 34 (03) 318-327
    PubMedGoogle Scholar
  • 11 Mark DB, Hlatky MA, Califf RM. et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995; 332 (21) 1418-1424
    CrossrefPubMedGoogle Scholar
  • 12 Ouriel K. Urokinase and the US Food and Drug Administration. J Vasc Surg 1999; 30 (05) 957-958
    CrossrefPubMedGoogle Scholar
  • 13 Collen D, Lijnen HR. The tissue-type plasminogen activator story. Arterioscler Thromb Vasc Biol 2009; 29 (08) 1151-1155
    CrossrefPubMedGoogle Scholar
  • 14 Nordt TK, Bode C. Thrombolysis: newer thrombolytic agents and their role in clinical medicine. Heart 2003; 89 (11) 1358-1362
    CrossrefPubMedGoogle Scholar
  • 15 Walley T, Dundar Y, Hill R, Dickson R. Superiority and equivalence in thrombolytic drugs: an interpretation. QJM 2003; 96 (02) 155-160
    CrossrefPubMedGoogle Scholar
  • 16 Adivitiya, Khasa YP. The evolution of recombinant thrombolytics: current status and future directions. Bioengineered 2017; 8 (04) 331-358
    CrossrefPubMedGoogle Scholar
  • 17 Benedict CR, Refino CJ, Keyt BA. et al. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA. Circulation 1995; 92 (10) 3032-3040
    CrossrefPubMedGoogle Scholar
  • 18 Van De Werf F, Adgey J, Ardissino D. et al; Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999; 354 (9180): 716-722
    CrossrefPubMedGoogle Scholar
  • 19 Grunwald MR, Hofmann LV. Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol 2004; 15 (04) 347-352
    CrossrefPubMedGoogle Scholar
  • 20 Vedantham S, Piazza G, Sista AK, Goldenberg NA. Guidance for the use of thrombolytic therapy for the treatment of venous thromboembolism. J Thromb Thrombolysis 2016; 41 (01) 68-80
    CrossrefPubMedGoogle Scholar
  • 21 Enden T, Haig Y, Kløw NE. et al; CaVenT Study Group. Long-term outcome after additional catheter-directed thrombolysis versus standard treatment for acute iliofemoral deep vein thrombosis (the CaVenT study): a randomised controlled trial. Lancet 2012; 379 (9810): 31-38
    Google Scholar
  • 22 Semba CP, Bakal CW, Calis KA. et al; Advisory Panel on Catheter-Directed Thrombolytic Therapy. Alteplase as an alternative to urokinase. J Vasc Interv Radiol 2000; 11 (03) 279-287
    CrossrefPubMedGoogle Scholar
  • 23 Benenati J, Shlansky-Goldberg R, Meglin A, Seidl E. Consultants from the Reteplase and Abciximab for Peripheral Vascular Interventions Conference; Society for Cardiovascular and Interventional Radiology. Thrombolytic and antiplatelet therapy in peripheral vascular disease with use of reteplase and/or abciximab. The SCVIR Consultants' Conference; May 22, 2000; Orlando, FL. J Vasc Interv Radiol 2001; 12 (07) 795-805
    PubMedGoogle Scholar
  • 24 Patel NH, Krishnamurthy VN, Kim S. et al; CIRSE and SIR Standards of Practice Committees. Quality improvement guidelines for percutaneous management of acute lower-extremity ischemia. J Vasc Interv Radiol 2013; 24 (01) 3-15
    CrossrefPubMedGoogle Scholar
  • 25 Razavi MK, Wong H, Kee ST, Sze DY, Semba CP, Dake MD. Initial clinical results of tenecteplase (TNK) in catheter-directed thrombolytic therapy. J Endovasc Ther 2002; 9 (05) 593-598
    CrossrefPubMedGoogle Scholar
  • 26 Vedantham S, Salter A, Lancia S, Lewis L, Thukral S, Kahn SR. Clinical outcomes of a pharmacomechanical catheter-directed venous thrombolysis strategy that included rheolytic thrombectomy in a multicenter randomized trial. J Vasc Interv Radiol 2021; 32 (09) 1296-1309 .e7
    CrossrefPubMedGoogle Scholar
  • 27 Kaufman C, Kinney T, Quencer K. Practice trends of fibrinogen monitoring in thrombolysis. J Clin Med 2018; 7 (05) 111
    CrossrefPubMedGoogle Scholar